Table 4. Disposition of the participants at week 48.

All participants	135
HIV-1 VL < 50 c/mL, n (%)	115 (85.2)
DISCONTINUATION, n (%)	6 (4.4)
• HIV-1 VL > 200 copies/mL	1 (0.7)
• CNS AE	3 (2.2)
• M184V mutation in bDRT	2 (1.5)
LOST TO FOLLOW- UP, n (%)	14 (10.4)

AE = adverse event; CNS = Central nervous system adverse event; VL = viral load; bDRT = Baseline drug resistance testing.